24 04, 2024

EVscale™ platform

2024-04-24T13:30:23+02:00April 24th, 2024|biomarker, Evercyte, exosomes, extracellular vesicle, microRNA services, microRNAs, miND spike ins, NGS, Phoenestra, sequencing, smallRNA|0 Comments

The EVscale™ platform, developed by Evercyte, Phoenestra, and TAmiRNA, offers a comprehensive solution for pharmaceutical and biotech manufacturers requiring exosomes and EVs at commercial scale. Drawing on the combined expertise of the three partners, EVscale™ provides customizable projects, including specific cell sourcing, EV characterization, scalable manufacturing, and linking EV biological functions to RNA and protein EV components. EVscale™ advantages: Offers a fundamental advantage over conventional sourcing of therapeutic exosomes from primary cells, eliminating donor-to-donor variability and other issues like scaling difficulties, variable process performance, inconsistent batch quality, and under-developed downstream processing technologies. Provides a unique one-stop-shop offer, allowing customers to tailor end-product parameters based on their project’s specific needs. By combining miRNomics with transcriptomic and proteomic analyses, [...]

10 04, 2024

Eager to lern more about Sepsis-associated acute kidney injury?

2024-04-10T13:16:00+02:00April 10th, 2024|biomarker, biomarkers, microRNA services, microRNAs, microstructure, miND spike ins, NGS, sequencing, smallRNA, Vivomicx|Comments Off on Eager to lern more about Sepsis-associated acute kidney injury?

We are pleased to share our latest publication, a collaborative effort with TAmiRNA, titled 'Sepsis-Induced Heterogeneous Transcription of Coagulation- and Inflammation-Associated Genes in Renal Microvasculature,' which has been published in Thrombosis Research. Through the integration of TAmiRNA's high-sensitivity gene expression profiling techniques (RT-qPCR and smallRNAseq/RNAseq) and the advanced laser microdissection technology from Dutch company Vivomicx, our study unveils the diverse transcriptional responses of microvascular compartments to sepsis-associated acute kidney injury (SA-AKI). Our findings demonstrate that distinct changes occur in the expression of coagulation- and inflammation-related genes across microvascular compartments in response to SA-AKI. This heterogeneity underscores the complexity of the microvascular response to sepsis and highlights potential avenues for targeted therapeutic intervention. Moving forward, our research will [...]

4 04, 2024

Exciting news!

2024-04-04T13:16:30+02:00April 4th, 2024|biomarker, biomarkers, Illumina NewSeq2000, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA|Comments Off on Exciting news!

We just received the Illumina NextSeq 2000 machine, marking a significant milestone in our journey towards cutting-edge research and innovation. This powerful instrument will drive our NGS services and allow us to deliver results quicker than ever before.

5 03, 2024

TAmiRNA at RNA Leaders conference in Basel

2024-03-05T08:19:26+01:00March 5th, 2024|biomarker, biomarkers, microRNAs, NGS|Comments Off on TAmiRNA at RNA Leaders conference in Basel

TAmiRNA CEO/CSO Matthias Hackl will attend the RNA Leaders conference in Basel next week to speak about the recent development of reliable miRNA safety biomarkers and their potential to indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes. Reach out to Matthias directly to meet with him before or after his presentation on Wednesday, March 13th at 12:25 pm and discuss our latest developments and how TAmiRNA's  services can assist your business!

13 02, 2024

Webinar – COST Action AtheroNET

2024-02-13T11:20:12+01:00February 13th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on Webinar – COST Action AtheroNET

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 CET Registration Link: https://lnkd.in/dVDDYKcA Reach out to Matthias directly after his webinar and discuss our latest developments and how TAmiRNA’s  miND spike ins and small RNA sequencing service can assist your business!

26 01, 2024

TAmiRNA ‘2023 In Review’

2024-01-26T11:44:38+01:00January 26th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on TAmiRNA ‘2023 In Review’

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!

17 01, 2024

Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins

2024-01-17T11:03:50+01:00January 17th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs|Comments Off on Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins

We want to draw your attention to the latest collaborative publication by TAmiRNA scientist Marianne Pultar: “Analysis of extracellular vesicle microRNA profiles reveals distinct blood and lymphatic endothelial cell origins” published in the Journal of Extracellular Biology. By applying TAmiRNA´s unique small RNA-seq and RNA-seq workflows, this study provides important insights into the secretory behavior of endothelial cell-derived extracellular vesicles (EVs) and their microRNA cargo. In future, these findings can support the identification and development of non-invasive and cell-type specific biomarkers in liquid biopsis. Click here to learn more about our EV service click here to read the paper

15 01, 2024

Circulating endothelial extracellular vesicle signatures correspond with ICU requirement

2024-01-15T10:16:16+01:00January 15th, 2024|biomarker, biomarkers, CoV-2, diagnose disease, exosomes, extracellular vesicle, microRNA services, microRNAs|Comments Off on Circulating endothelial extracellular vesicle signatures correspond with ICU requirement

We want to draw your attention to the latest publication in cooperation with TAmiRNA – “Circulating endothelial extracellular vesicle signatures correspond with ICU requirement: an exploratory study in COVID-19 patients” published in Intensive Care Medicine Experimental. Using TAmiRNA’s expertise in the field of EV characterization, we found that endothelial EVs and associated miRNAs could be promising candidates for the diagnosis of patients with COVID-19. Click here to learn more about this service click here to read the paper

10 01, 2024

TAmiRNA partners with Techtum Lab

2024-01-10T09:45:03+01:00January 10th, 2024|microRNA, microRNA services, microRNAs, miND spike ins, NGS, PCR testing service, smallRNA, Techtum Lab|Comments Off on TAmiRNA partners with Techtum Lab

TAmiRNA has entered an exclusive distribution agreement with Techtum Lab for the sales of their products in the Nordics. Techtum Lab is a full service supplier and partner to clinical and research molecular biology laboratories and looks back at >45 years of experience in the Nordic region. TAmiRNA complements Techtum’s NGS portfolio with the miND Spike-Ins, a unique set of controls for small RNA sequencing experiments. Furthermore, Techtum partners with TAmiRNA to make customized RNA sequencing services accessible to those customers who are looking for external support with analysing their sample’s RNA content.

22 11, 2023

TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

2023-11-22T11:22:16+01:00November 22nd, 2023|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, NGS, PCR testing service, SPI|Comments Off on TAmiRNA meets Japanese Pharma to present microRNA Biomarker Discovery Solutions

Matthias Hackl, CEO/CSO of TAmiRNA, visited Japan between November 11th and 18th to join Summit Pharmaceutical international to introduce TAmiRNA to 12 medium- and large-size pharmaceutical companies. Matthias presented information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs. In addition, Matthias joined a seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products” organized by the local partner Summit Pharmaceutical International. In his talk, Matthias explained to >70 representatives from Japanese Universities and Pharmaceutical industry TAmiRNA’s the advantages of full molecular characterization of exosomes and extracellular vesicles (EVs) to determine EV composition, consistency, and mode-of-action.

Go to Top